Belsomra (Suvorexant) Cost in Oklahoma: Prices, Insurance, and Savings in 2026

Belsomra is the brand name for suvorexant, an FDA-approved dual orexin receptor antagonist (DORA) used for insomnia. It is a DEA Schedule IV controlled substance, available only by prescription, dosed at 10 mg or 20 mg taken once at bedtime. It is not the same drug as lemborexant (Dayvigo), a related but separate DORA, or the Z-drugs zolpidem (Ambien) and eszopiclone (Lunesta), which work through a different mechanism.

The honest answer for a reader trying to price Belsomra in Oklahoma is that no single verified number exists for "the" 2026 cost. Manufacturer list price, insurer negotiated rates, pharmacy cash price, and compounded-pharmacy price are four different figures that change independently of each other and are not published in a way this article can verify from primary sources. What is stable and verifiable is suvorexant's FDA-approved indication, its controlled-substance schedule, its dosing range, and the general coverage pathways (commercial insurance, Medicaid, cash pay, compounded 503A preparation) that apply in every state, including Oklahoma.

What is established vs. what needs verification

Established from FDA labeling and DEA scheduling:

• Suvorexant (Belsomra) is FDA-approved for insomnia characterized by difficulty with sleep onset and/or sleep maintenance, approved in 2014.
• It is classified as a Schedule IV controlled substance.
• Approved dosing starts at 10 mg at bedtime with at least 7 hours before planned waking, and may be increased to a maximum of 20 mg. Strong CYP3A inhibitors are contraindicated with suvorexant, and moderate CYP3A inhibitors require a dose cap, per FDA labeling. (FDA drug label database)
• Suvorexant carries a boxed warning for complex sleep behaviors such as sleepwalking and sleep-driving, and can cause next-day somnolence.
• Compounding of suvorexant by a licensed 503A pharmacy for an individual patient with a valid prescription is generally understood to be legal under federal law when a prescriber determines the commercial product does not meet the patient's needs, per general federal compounding rules.
• Federal telehealth flexibilities for prescribing certain controlled substances, including Schedule IV medications, have been extended by DEA at various points since 2020, but the exact rules in effect at any given date change and must be checked against current DEA guidance rather than assumed. (DEA Diversion Control Division)

Not established or not verifiable from the sources available for this draft:

• A specific manufacturer list price, a specific Oklahoma average cash price, or a specific insurer copay tier for Belsomra. These figures move month to month and pharmacy to pharmacy, and no primary source in this draft's evidence base supports a precise 2026 dollar figure for Oklahoma.
• Whether Oklahoma Medicaid (SoonerCare) currently covers or excludes Belsomra, and under what prior-authorization criteria. Preferred drug lists are updated on a recurring cycle and the current status must be confirmed directly with SoonerCare or the Oklahoma Health Care Authority rather than assumed from a general description.
• Specific commercial insurer tier placements (for example, a named carrier's copay range) for Oklahoma plans. Formularies vary by employer group and plan year even within the same insurer.
• A precise clinical trial statistic for suvorexant's effect size (for example, minutes of added sleep time) is plausible based on the pivotal trials that supported FDA approval, but this draft could not confirm a specific citation for that number against verified primary literature, so it is described qualitatively below rather than with a specific figure.

The plausible-but-unconfirmed middle ground is important for a YMYL cost page: general patterns (branded specialty sleep drugs commonly cost more than generic alternatives; manufacturer savings programs commonly reduce commercial-plan copays; compounded preparations are commonly less expensive than brand product) are reasonable expectations based on how pharmaceutical pricing typically works, but none of them substitute for checking your own plan, pharmacy, and prescription on the date you fill it.

Coverage pathways an Oklahoma patient may encounter

Commercial insurance. Most commercial plans require prior authorization or step therapy (trying a preferred, usually generic, sleep medication first) before covering a branded DORA like Belsomra. Whether a specific Oklahoma plan requires this, and what the resulting copay is, depends on that plan's current formulary. Call the number on your insurance card or check your plan's online formulary before assuming a price.

Oklahoma Medicaid (SoonerCare). Medicaid programs commonly place non-preferred branded drugs behind prior authorization or step therapy requirements favoring older, less expensive agents such as generic zolpidem or trazodone. Whether Belsomra specifically is covered, excluded, or available only through an exception process in Oklahoma's current SoonerCare formulary should be confirmed directly with the Oklahoma Health Care Authority, since formulary status changes and this draft cannot verify the current status from a stable primary source.

Manufacturer savings support. Merck has historically offered patient support programs for Belsomra, which may include a copay savings card for commercially insured patients and a patient assistance program for uninsured or low-income patients. Eligibility rules, savings caps, and income thresholds for these programs change and should be confirmed at the manufacturer's official site rather than assumed from a secondary description.

Cash pay and discount cards. Retail cash prices vary by pharmacy chain, location, and whether a discount card (GoodRx, RxSaver, SingleCare, and similar) is applied at the register. These prices are pharmacy-set and change frequently; the only reliable way to know your price is to check a pricing tool or call the specific pharmacy on the day you plan to fill.

Compounded suvorexant through a 503A pharmacy. This is a legal option in Oklahoma when a prescriber determines the commercial tablet does not meet a patient's needs (for example, an inactive-ingredient sensitivity or a need for a non-standard strength) and a licensed 503A pharmacy compounds against a patient-specific prescription. Compounded products are not FDA-approved and their bioavailability may differ from the brand tablet; this tradeoff should be discussed with the prescribing clinician. Confirm any compounding pharmacy's current Oklahoma Board of Pharmacy license before using it.

Mechanism, in brief

Suvorexant blocks orexin receptors (OX1R and OX2R) in the hypothalamus, reducing wake-promoting orexin signaling. This is a different mechanism from benzodiazepines and Z-drugs, which enhance GABA-mediated inhibition. Loss of orexin-producing neurons is the underlying mechanism of narcolepsy type 1, which is part of why the orexin system was identified as a wakefulness-regulating pathway. A pivotal randomized trial supporting FDA approval reported improved sleep onset and maintenance measures compared to placebo over the trial period; the exact magnitude of that effect should be verified against the current FDA label or a verified copy of the published trial rather than repeated from a secondary source.

Comparing suvorexant with other Oklahoma-available insomnia treatments

Generic zolpidem and generic trazodone (used off-label for insomnia) are typically far less expensive as generics than any brand-name DORA, which is why Medicaid and many commercial plans place them as preferred, first-line options. Lemborexant (Dayvigo) is the other FDA-approved DORA and is generally priced similarly to Belsomra at the brand level, with the choice between the two often driven by formulary placement rather than a clear clinical superiority of one over the other. The American Academy of Sleep Medicine's guideline framework for chronic insomnia in adults recommends behavioral treatment, particularly cognitive behavioral therapy for insomnia (CBT-I), as a first-line approach, with pharmacologic options, including DORAs, considered when behavioral treatment alone is insufficient or unavailable. Confirm the current guideline recommendations directly rather than relying on a paraphrase, since guideline documents are periodically updated.

Verification checklist: stable facts vs. facts you must confirm before paying

Use this before assuming any price or coverage decision from this or any other cost page.

Stable facts (federal/clinical, unlikely to change year to year):

• Suvorexant is FDA-approved for insomnia and is DEA Schedule IV.
• Approved dosing range is 10-20 mg at bedtime, with a boxed warning for complex sleep behaviors.
• Strong CYP3A inhibitors are contraindicated; moderate CYP3A inhibitors require a lower dose, per FDA labeling.
• 503A pharmacy compounding of suvorexant is legal under federal law with a valid patient-specific prescription, subject to state pharmacy board licensure.
• These facts can be checked against the FDA label and FDA compounding guidance at any time.

Date-sensitive facts (confirm on the day you plan to fill or enroll):

• Current Oklahoma SoonerCare Medicaid coverage status and any prior-authorization or step-therapy criteria for Belsomra, confirmed directly with the Oklahoma Health Care Authority.
• Your specific commercial plan's current formulary tier, copay, and step-therapy requirement for Belsomra, confirmed by calling the number on your insurance card.
• Current manufacturer savings card eligibility rules and any annual savings cap, confirmed at the manufacturer's official patient support page.
• Current cash price at your specific pharmacy, with and without a discount card, confirmed at the pharmacy or through a live pricing tool.
• Current DEA telehealth prescribing rules for Schedule IV controlled substances in effect on the date of your visit, confirmed at DEA's diversion control site.
• Current license status of any compounding pharmacy you are considering, confirmed through the Oklahoma Board of Pharmacy's license lookup.

If you cannot check a box, treat the associated number or rule as unverified rather than acting on it.

When to involve your prescriber rather than shop on price alone

Cost should not be the only factor in choosing between suvorexant, lemborexant, a Z-drug, trazodone, or CBT-I. A prescriber who knows your insomnia subtype, other medications (especially CYP3A inhibitors), and coexisting conditions is better positioned to judge whether a lower-cost alternative is clinically appropriate for you, or whether suvorexant's mechanism is specifically indicated. If you experience sleepwalking, sleep-driving, or other complex behaviors while asleep, or worsening daytime drowsiness affecting safety (for example, driving), contact your prescriber promptly rather than waiting for a routine follow-up.